Legend Biotech Corporation (NASDAQ:LEGN) Q4 2024 Earnings Call Transcript March 11 ... track and we continue to maintain a ...

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years ...

HC Wainwright also issued estimates for Legend Biotech’s Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.07) EPS. Get Legend Biotech alerts: ...

Legend Biotech shares dipped 0.8% following the earnings release, suggesting a relatively muted market reaction to the results. This article was generated with the support of AI and reviewed by an ...

Cash and Equivalents: $1.1 billion at the end of 2024. Legend Biotech Corp (NASDAQ:LEGN) reported a 110% year-over-year increase in net trade sales of CARVYKTI, reaching approximately $334 million ...

As a result of Carvykti’s strong performance, Legend swung to a net income in Q4 of $26.284 million, or $0.07 per share. Turning to the balance sheet, as of December 2024, Legend held $286.749 ...